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The purpose of the present study was to characterize the adenosine transport system(s) at the inner blood–retinal barrier (inner BRB). A
conditionally immortalized rat retinal capillary endothelial cell line (TR-iBRB2), used as an in vitro model of the inner BRB, expresses
equilibrative nucleoside transporter 1 (ENT1), ENT2, concentrative nucleoside transporter 2 (CNT2), and CNT3 mRNAs. TR-iBRB2 cells
exhibited an Na+-independent and concentration-dependent [3H]adenosine uptake with a Michaelis–Menten constant of 28.5 μM and a maximum
uptake rate of 814 pmol/(min mg protein). [3H]Adenosine uptake by TR-iBRB2 cells was strongly inhibited by 2 mM adenosine, inosine, uridine,
and thymidine. On the other hand, this process was not inhibited by 100 nM nitrobenzylmercaptopurine riboside and dipyridamole. These uptake
studies suggest that ENT2 is involved in [3H]adenosine uptake by TR-iBRB2 cells. Quantitative real-time PCR revealed that the expression of
ENT2 mRNA is 5.5-fold greater than that of ENT1 mRNA. An in vivo study suggested that [3H]adenosine is transported from the blood to the
retina and significantly inhibited by adenosine and thymidine. The results of this study show that ENT2 most likely mediates adenosine transport
at the inner BRB and is expected to play an important role in regulating the adenosine concentration in the retina.
© 2006 Elsevier B.V. All rights reserved.Keywords: Blood–retinal barrier; Adenosine; Nucleoside transporter1. Introduction
Adenosine is an important intercellular signaling molecule
and it plays a number of roles in retinal neurotransmission,
blood flow, vascular development, and response to ischemia
[1,2]. These effects are mediated through cell-surface adenosine
receptors, so that the effect of adenosine in the retina is
markedly influenced by the adenosine concentration in the
retinal interstitial fluid. Most of the adenosine in the retinal
interstitial fluid is thought to originate from the catabolism of
adenosine monophosphate catalyzed by membrane-bound ecto-Abbreviations: BRB, blood–retinal barrier; TR-iBRB2, conditionally
immortalized rat retinal capillary endothelial cell line; NBMPR, nitrobenzyl-
mercaptopurine riboside; ENT, equilibrative nucleoside transporter; CNT,
concentrative nucleoside transporter; ECF, extracellular fluid; Vd, apparent
retina-to-plasma concentration ratio; RB, apparent blood-to-plasma concentra-
tion ratio; Kin, retina, apparent retinal uptake clearance of [
3H]adenosine; RUI,
retinal uptake index; BBB, blood–brain barrier
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doi:10.1016/j.bbamem.2006.01.0115′-nucleotidase (CD73) [1], which is localized in the innermost
process of Müller cells [3]. Consequently, almost all of the
retinal adenosine is distributed in the neighborhood of the
innermost process of Müller cells in the ganglion cell layer,
inner plexiform layer, and inner nuclear layer [4]. Retinal blood
vessels are also distributed in ganglion cell layer, inner and
outer plexiform layers, and inner nuclear layer [5] and form the
inner blood–retinal barrier (inner BRB) which strictly regulates
molecular transport between the blood and the retinal interstitial
fluid [6]. Polska et al. [7] have reported that exogenous
adenosine introduced via infusion increases the optic nerve head
blood flow in healthy humans. Since adenosine in the blood
needs to penetrate the inner BRB in order to activate its
receptors expressed in vascular smooth muscle cells and
increase blood flow, it has been suggested that adenosine
transport system(s) at the inner BRB also have the ability to
regulate the adenosine concentration in the retinal interstitial
fluid and modulate retinal functions.
Two classes of nucleoside transporters have been described.
The Na+-independent equilibrative nucleoside transporter
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while the Na+-dependent concentrative nucleoside transporter
(CNT) consists of CNT1 (Slc28a1), CNT2 (Slc28a2), and
CNT3 (Slc28a3) [9]. They affect the concentration of adenosine
available to its receptors in some organs. The inhibition of
ENT1-mediated transport by the selective inhibitor, nitroben-
zylmercaptopurine riboside (NBMPR), and consequent eleva-
tion of the adenosine concentration modulates glutamatergic
synaptic transmission via presynaptic A1 receptors in the
superficial dorsal horn of the spinal cord in rats [10]. Moreover,
the A1 receptor-mediated chronotropic effect of adenosine is
potentiated by the ENT1 inhibitor, dipyridamole, in the
sinoatrial node of the guinea pig heart [11]. In the retina, it
has been reported that [3H]adenosine uptake and its inhibition
by NBMPR take place in the retinal ganglion cell layer and
inner nuclear layer of rabbits [12] and the cultured retinal
neurons and photoreceptors of the chick embryo [13]. However,
there is no information at all on the nucleoside transport system
at the inner BRB although it would be very useful to have more
information about adenosine transport mechanisms at the inner
BRB in order to understand the regulation of the adenosine
concentration in the neural retina.
The purpose of the present study was to elucidate the
molecular mechanism of adenosine transport at the inner BRB.
The characteristics and functions of adenosine transport at the
inner BRB were examined using a conditionally immortalized
rat retinal capillary endothelial cell line (TR-iBRB2) as an in
vitro model of the inner BRB [14] and in vivo vascular injection
techniques. TR-iBRB2 cells possess endothelial markers and
glucose transporter 1 (GLUT1), P-glycoprotein, creatine
transporter (CRT), and L-type amino acid transporter 1
(LAT1) [14–17], which are expressed at the inner BRB in
vivo. Accordingly, TR-iBRB2 cells maintain certain in vivo
functions and are a suitable in vitro model for the inner BRB.
2. Materials and methods
2.1. Animals
Male Wistar rats, weighing 250–300 g, were purchased from SLC
(Shizuoka, Japan). The investigations using rats described in this report
conformed to the provisions of the Animal Care Committee, Toyama Medical
and Pharmaceutical University (currently University of Toyama) (#2003-48) and
the ARVO Statement on the Use of Animals in Ophthalmic and Vision Research.
2.2. Cell culture
TR-iBRB2 cells were established from a transgenic rat harboring
temperature-sensitive SV 40 large T-antigen gene [14]. TR-iBRB2 cells were
seeded onto rat tail collagen type I-coated culture flasks (BD Biosciences,
Bedford, MA). The cells were cultured in Dulbecco's modified Eagle's medium
supplemented with 10% fetal bovine serum (Moregate, Bulimbra, Australia) at
33 °C in a humidified atmosphere of 5% CO2/air. The permissive temperature
for TR-iBRB2 cell culture is 33 °C due to the presence of temperature-sensitive
SV40 large T-antigen [14].
2.3. RT-PCR analysis
Total cellular RNA was prepared by using an Rneasy Kit (Qiagen, Hilden,
Germany). Single-strand cDNA was made from total RNA by reversetranscription (RT) using oligo dT primer. The polymerase chain reaction
(PCR) was performed with ENT1 (Slc29a1), ENT2 (Slc29a2), CNT1 (Slc28a1),
CNT2 (Slc28a2), or CNT3 (Slc28a3) specific primers through 40 cycles of 94 °C
for 30 sec, 60–62 °C for 30 sec, and 72 °C for 1 min. The sequences of the
specific primers were as follows: the sense sequence was 5′-GCC AAC TAC
ACA GCC CCC ATC A-3′ and the antisense sequence was 5′-TCA GCA GTC
ACA GCA GGG AAC AA-3′ for rat ENT1 (GenBank accession number
NM_031684), the sense sequence was 5′-CCTACAGCA CCC TCT TCC TCA
GT-3′ and the antisense sequence was 5′-CCC AGC CAATCC ATG ACG TTG
AA-3′ for rat ENT2 (GenBank accession number NM_031738) [18], the sense
sequence was 5′-CAA CAC ACA GAG GCA AAG AGA GTC-3′ and the
antisense sequence was 5′-CCA CAC CAG CAG CAA GGG CTA G-3′ for rat
CNT1 (GenBank accession number NM_053863), the sense sequence was 5′-
GGAAGA GTG ACT TGT GCAAGC TTG-3′ and the antisense sequence was
5′-GTG CTG GTA TAG AGG TCA CAG CA-3′ for rat CNT2 (GenBank
accession number NM_031664), and the sense sequence was 5′-CTG TCT TTT
GGG GAA TTG GAC TGC-3′ and the antisense sequence was 5′-CCA GTA
GTG GAG ACT CTG TTT GC-3′ for rat CNT3 (GenBank accession number
NM_080908). The PCR products were separated by electrophoresis on an
agarose gel in the presence of ethidium bromide and visualized under ultraviolet
light. The molecular identity of the resultant product was confirmed by sequence
analysis using a DNA sequencer (ABI PRISM 310; Applied Biosystems, Foster
City, CA).
2.4. [3H]Adenosine uptake by TR-iBRB2 cells
The [2,8-3H]adenosine ([3H]adenosine, 35.9 Ci/mmol, Amersham Life
Science, Buckinghamshire, UK) uptake by TR-iBRB2 cells was measured
according to a previous report [15]. Briefly, TR-iBRB2 cells (1×105 cells/cm2)
were cultured at 33 °C for 48 hours on rat tail collagen type I-coated 24-well
plates (BD Biosciences) and washed with 1 mL extracellular fluid (ECF) buffer
consisting of 122 mM NaCl, 25 mM NaHCO3, 3 mM KCl, 1.4 mM CaCl2, 1.2
mMMgSO4, 0.4 mM K2HPO4, 10 mM D-glucose and 10 mM HEPES (pH 7.4)
at 37 °C. Uptake was initiated by applying 200 μL ECF buffer containing 0.1
μCi [3H]adenosine (14 nM) at 37 °C in the presence or absence of inhibitors.
Na+-free ECF buffers were prepared by equimolar replacement of NaCl and
NaHCO3 with choline chloride and choline bicarbonate, respectively. After a
predetermined period, uptake was terminated by removing the solution, and
cells were immersed in ice-cold ECF buffer. The cells were then solubilized in
1 N NaOH and subsequently neutralized. An aliquot was taken for measurement
of radioactivity and protein content using, respectively, a liquid scintillation
counter (LS6500; Beckman-Coulter, Fullerton, CA) and a DC protein assay kit
(Bio-rad, Hercules, CA) with bovine serum albumin as a standard.
For kinetic studies, the Michaelis–Menten constant (Km) and maximum rate
(Jmax) of adenosine uptake were calculated from the following equation using
the nonlinear least-square regression analysis program, MULTI [19].
J ¼ Jmax  ½S=ðKm þ ½SÞ ð1Þ
where [S] and J are, respectively, the concentration of adenosine and the carrier-
mediated component of the uptake rate of adenosine at 5 min estimated by
subtracting the uptake rate in the presence of 10 mM non-radiolabeled
adenosine, which represents a non-saturable component of the uptake rate.
2.5. Quantitative real-time PCR
Quantitative real-time PCR was performed using an ABI PRISM 7700
sequence detector system (Applied Biosystems) with 2× SYBR Green PCR
Master Mix (Applied Biosystems) according to the manufacturer's protocol. To
quantify the amount of specific mRNA in the samples, a standard curve was
generated for each run using the plasmid (pGEM-T Easy Vector; Promega,
Madison, WI) containing the gene of interest. This enabled standardization of
the initial mRNA content of cells relative to the amount of β-actin. The PCRwas
performed using ENT1, ENT2, or β-actin-specific primers and the cycling
parameters are those given above. The sequences of the specific primers of rat β-
actin (GenBank accession number NM_031144) were as follows: sense, 5′-TCA
TGAAGT GTGACG TTGACATCCGT-3′ and antisense, 5′-CCTAGAAGC
ATT TGC GGT GCA CGATG-3′.
Fig. 1. RT-PCR analysis of ENT1 (A), ENT2 (B), CNT1 (C), CNT2 (D), and
CNT3 (E) expression in TR-iBRB2 cells. Lane 1: positive control; lane 2: rat
retina; lane 3: TR-iBRB2 cells. *: in the absence of reverse transcriptase for the
respective left-hand lane. Rat brain (ENT1 and ENT2), kidney (CNT1), liver
(CNT2), and small intestine (CNT3) were used as positive controls.
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The apparent retinal uptake clearance of [3H]adenosine (Kin, retina) [μL/(min
g retina)] from the circulating blood to the retina was determined by integration
plot analysis as described previously [15]. Briefly, the rats were anesthetized
with an intramuscular injection of ketamine-xylazine (1.22 mg xylazine and 125
mg ketamine/kg) and then [3H]adenosine (12 μCi/head) was injected into the
femoral vein. After collection of blood samples, rats were decapitated, and the
retinas were removed. The retinas were dissolved in 2 N NaOH and
subsequently neutralized. The radioactivity was measured in a liquid
scintillation counter. As an index of the retinal distribution characteristics of
[3H]adenosine, the apparent retina-to-plasma concentration ratio (Vd) was used.
This ratio [Vd(t)] (mL/g retina) was defined as the amount of [
3H] per gram retina
divided by that per milliliter plasma, calculated over the time-period of the
experiment (t). The apparent blood-to-plasma concentration ratio (RB) was
also measured to examine the [3H]adenosine uptake into the blood cells. The
Kin, retina can be described by following Eq. (2):
VdðtÞ ¼ Kin; retina  AUCðtÞ=CpðtÞ þ Vi ð2Þ
where AUC(t) (dpm min/mL), Cp(t) (dpm/mL), and Vi (mL/g retina) represent
the area under the plasma concentration time curve of [3H]adenosine from
time 0 to t, the plasma [3H]adenosine concentration at time t, and the rapidly
equilibrated distribution volume of [3H]adenosine in the retina, respectively.
Vi is usually comparable with the vascular volume of the retina.
The inhibitory effect of nucleosides on the blood-to-retina transport of [3H]
adenosine was evaluated by the retinal uptake index (RUI) method [20,21].
Briefly, the rats were anesthetized with an intramuscular injection of ketamine-
xylazine and then 200 μL of injection solution was injected into the common
carotid artery. The injection solution consisted of Ringer–HEPES buffer (141
mMNaCl, 4 mMKCl, 2.8 mMCaCl2, 10 mMHEPES, pH 7.4) which contained
both a test compound, 10 μCi [3H]adenosine or D-[1-3H(N)]mannitol ([3H]D-
mannitol, 17 Ci/mmol, PerkinElmer Life Sciences, Boston, MA), and a
reference compound, 0.1 μCi n-[1-14C]butanol ([14C]n-butanol, 2 mCi/mmol,
American Radiolabeled Chemicals, St. Louis, MO), in the presence or absence
of inhibitors. Rats were decapitated at 15 sec after injection, and the retina was
removed. The retina was dissolved in 2 N NaOH and subsequently neutralized.
The radioactivity was measured in a liquid scintillation counter. In this study, the
RUI value was used as an index of the retinal distribution characteristics of [3H]
adenosine and can be described by following Eq. (3):
RUI ¼ ½
3H=½14Cðdpm in the retinaÞ
½3H=½14Cðdpm in the injection solutionÞ  100 ð3Þ
2.7. Data analysis
Unless otherwise indicated, all data represent means±S.E.M. An unpaired,
two-tailed Student's t-test was used to determine the significance of differences
between two groups. Statistical significance of differences among means of
several groups was determined by one-way analysis of variance followed by the
modified Fisher's least-squares difference method.3. Results
3.1. Expression of nucleoside transporters in TR-iBRB2 cells
RT-PCR analysis was performed to examine the expression
of ENT and CNT mRNAs in the rat retina and TR-iBRB2 cells.
As shown in Fig. 1, the expression of ENT1, ENT2, CNT1, and
CNT2 in the retina was detected at 431, 562, 479, and 298 bp,
respectively. Of the four transporters, the expression of ENT1,
ENT2, and CNT2 was also detected in TR-iBRB2 cells. The
expression of CNT3 was not detected in the retina, however, and
only a minor band of CNT3 was detected in TR-iBRB2 cells.3.2. [3H]Adenosine uptake by TR-iBRB2 cells
To analyze the kinetics and characteristics of adenosine
transport at the inner BRB, [3H]adenosine uptake was
investigated using TR-iBRB2 cells as an in vitro model of
the inner BRB. The time-courses of [3H]adenosine uptake by
TR-iBRB2 cells in the presence or absence of Na+ are shown in
Fig. 2. [3H]Adenosine uptake increased linearly for at least 10
min. Na+-free conditions had no effect on [3H]adenosine
uptake until 10 min, supporting the hypothesis that [3H]
adenosine uptake by TR-iBRB2 cells is predominantly
mediated by ENT.
Fig. 3 shows the concentration-dependent uptake of
adenosine by TR-iBRB2 cells. The Eadie–Scatchard plot
(Fig. 3, inset) gave a single straight line, indicating that one
saturable process was involved in adenosine uptake by TR-
iBRB2 cells. Kinetic analysis of the uptake data using Eq. (1)
and nonlinear least-squares regression analysis, gave a Km of
28.5±2.2 μM and a Jmax of 814±45 pmol/(min mg protein)
(mean±S.D.).
The inhibition study was performed to characterize the [3H]
adenosine transport system in TR-iBRB2 cells (Table 1). Of the
nucleosides studied, adenosine, inosine, uridine, and thymidine,
Table 1
Effect of several inhibitors on [3H]adenosine uptake by TR-iBRB2 cells
Inhibitors Percentage of control
Control 100±1
2 mM Adenosine 4.75±0.13⁎⁎
2 mM Inosine 20.9±0.3⁎⁎
2 mM Uridine 35.7±1.5⁎⁎
2 mM Thymidine 24.4±0.6⁎⁎
2 mM Guanosine 60.3±1.7⁎⁎
2 mM Cytidine 70.5±3.4⁎⁎
2 mM Adenine 59.2±4.4⁎⁎
2 mM Hypoxanthine 71.8±3.8⁎⁎
100 nM Nitrobenzylmercaptopurine riboside
(NBMPR)
86.3±1.9 ⁎
10 μM NBMPR 43.9±1.8⁎⁎
100 μM NBMPR 10.5±0.6⁎⁎
100 nM Dipyridamole 92.0±1.4
1 μM Dipyridamole 42.3±1.7⁎⁎
10 μM Dipyridamole 8.14±0.16⁎⁎
[3H]Adenosine uptake (14 nM) was performed in the absence (control) or
presence of 2 mM inhibitors at 5 min and 37 °C. Each value represents the
mean±S.E.M. (n=4–12).
⁎ Pb0.05 significantly different from the control.
⁎⁎ Pb0.001, significantly different from the control.
Fig. 2. Time-course of [3H]adenosine uptake by TR-iBRB2 cells. The [3H]
adenosine (14 nM) uptake was performed at 37 °C in the presence (closed circle)
or absence (open circle) of Na+. Each point represents the mean±S.E.M. (n=4).
The error bar is smaller than the size of the symbol.
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more than 60%, while guanosine and cytidine, at a concentra-
tion of 2 mM, partially inhibited it by up to 40%. [3H]
Adenosine uptake was also inhibited by nucleobases, such as 2
mM adenine and 2 mM hypoxanthine, by 41% and 28%,
respectively. The Na+-independent nucleoside transport sys-
tems can be classified according to their sensitivity to NBMPR
and dipyridamole [8]. NBMPR and dipyridamole, at a
concentration of 100 nM, did not inhibit [3H]adenosine uptake,
while NBMPR (10 and 100 μM) and dipyridamole (1 and 10
μM) produced more than 50% inhibition. These results
represent NBMPR- and dipyridamole-insensitive transport of
adenosine in TR-iBRB2 cells.
3.3. Expression levels of ENT1 and ENT2 in TR-iBRB2 cells
To determine the dominant ENT in TR-iBRB2 cells,
quantitative real-time PCR analysis was performed to quantify
the mRNA expression levels of ENT1 and ENT2 in TR-iBRB2
cells (Fig. 4). The degree of mRNA expression compensatedFig. 3. Concentration-dependence of adenosine uptake by TR-iBRB2 cells.
The [3H]adenosine (14 nM) uptake was performed at 5 min and 37 °C. Each
point represents the mean±S.E.M. (n=4). Data were subjected to Michaelis–
Menten and Eadie–Scatchard analyses (inset). The Km is 28.5±2.2 μM and
Jmax is 814±45 pmol/(min mg protein) (mean±S.D.).with β-actin, for ENT1 and ENT2 was 3.27±0.29×10−3 and
1.81±0.33×10−2, respectively. Accordingly, the expression of
ENT2 mRNA was 5.5-fold greater than that of ENT1 in TR-
iBRB2 cells.
3.4. Blood-to-retina transport of [3H]adenosine
The in vivo blood-to-retina influx transport of adenosine
from the circulating blood to the retina through the BRB was
evaluated by an integration plot analysis after intravenous
administration of [3H]adenosine and application of the RUI
method using rats. The Kin, retina of [
3H]adenosine was found
to be 25.8±0.7 μL/(min g retina) (mean±S.D.) from the
slope of the integration plot (Fig. 5A). The Kin, retina includesFig. 4. The amount of ENT1 and ENT2 mRNA in TR-iBRB2 cells. The
amount of ENT1 and ENT2 mRNA in TR-iBRB2 cells was determined by
quantitative real-time PCR analysis. Data are the mean±S.E.M. (n=4). The
quantity of ENT1 mRNA relative to β-actin mRNA (ENT1/β-actin) in TR-
iBRB2 cells was 3.27±0.29×10−3, and that of ENT2 mRNA (ENT2/β-actin)
was 1.81±0.33×10−2.
Table 2
Retinal uptake index (RUI) of [3H]adenosine and [3H]D-mannitol






A test compound, [3H]adenosine or [3H]D-mannitol (10 μCi/head), and a
reference compound, [14C]n-butanol (0.1 μCi/head), were injected into the
common carotid artery in the presence or absence of 2 mM inhibitors. Each
value represents the mean±S.E.M. (n=3–9).
⁎ Pb0.05 significantly different from the control.
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erythrocytes) as well as the apparent influx clearance across
the BRB. In the case of adenosine, the apparent uptake
clearance into the retinal blood cannot be ignored, since the RB
of [3H]adenosine was increased with a slope of 0.0882 ±
0.0149 min−1 (mean±S.D.) (Fig. 5B). This behavior of
adenosine is consistent with a previous report showing that
adenosine accumulates in erythrocytes [22]. The vascular
volume in the retina was found to be 0.167±0.010 mL/g retina
from the Vi of [
3H]adenosine (Fig. 5A). By multiplying the
slope of the RB increment and the vascular volume in the
retina, the apparent uptake clearance into retinal blood found
to be 14.7±3.3 μL/(min g retina). Therefore, the apparent
influx clearance across the BRB was found to be 11.1±4.1 μL/
(min g retina). The influx transport of adenosine across the
BRB was also supported by the fact that the estimated RUI
value of [3H]adenosine was greater than that of [3H]D-
mannitol (Table 2). Moreover, adenosine and thymidine at a
concentration of 2 mM significantly decreased the RUI value
of [3H]adenosine to 70% and 75%, respectively, while 2 mM
cytidine had no effect. These results confirm the carrier-Fig. 5. Integration plot of the initial uptake of [3H]adenosine by the retina (A)
and blood-to-plasma concentration ratio (RB) (B) after intravenous administra-
tion. [3H]Adenosine (12 μCi/head) was injected into the femoral vein. Each
point represents the mean±S.E.M. (n=3–4).mediated transport of adenosine from the blood to the retina
across the BRB.
4. Discussion
The present study shows that the BRB is able to transport
[3H]adenosine (Fig. 5). The nucleoside transporters are
classified as an Na+-independent ENT and an Na+-dependent
CNT. TR-iBRB2 cells, an in vitro model of the rat inner BRB,
express both ENT and CNT mRNAs (Fig. 1), however, Na+-
independent uptake of [3H]adenosine by TR-iBRB2 cells (Fig.
2) suggests that ENT is predominantly involved in the
adenosine transport in TR-iBRB2 cells.
ENTs can be further sub-divided into two isoforms
according to their sensitivity to NBMPR [8]. The NBMPR-
sensitive (es) transporter, ENT1, is blocked by less than 100
nM NBMPR (IC50=4.6 nM) [23] while the NBMPR-
insensitive (ei) transporter, ENT2, requires more than 1 μM
NBMPR to inhibit nucleoside transport [23]. Although both
ENT1 and ENT2 have a variety of nucleoside substrates, ENT2
exhibits a lower affinity for guanosine and cytidine than ENT1
[24]. Moreover, only ENT2 is capable of low affinity transport
of nucleobases, such as adenine and hypoxanthine [25]. In TR-
iBRB2 cells, [3H]adenosine uptake was not inhibited by
NBMPR at 100 nM, but was inhibited at 10 and 100 μM
(Table 1). [3H]Adenosine uptake by TR-iBRB2 cells was
inhibited by nucleosides, however, the degree of inhibition by
adenosine, inosine, uridine, and thymidine was greater than that
produced by guanosine and cytidine. In addition to nucleosides,
[3H]adenosine uptake by TR-iBRB2 cells was partly inhibited
by nucleobases, such as adenine and hypoxanthine. Such forms
of inhibition in TR-iBRB2 cells are consistent with ENT2 rather
than ENT1. Moreover, quantitative real-time PCR analysis
clearly demonstrated that ENT2 is predominantly expressed in
TR-iBRB2 cells (Fig. 4). In the light of these findings, adenosine
transport in TR-iBRB2 cells is most likely mediated by ENT2.
[3H]Adenosine uptake by TR-iBRB2 cells was not inhibited
by dipyridamole at 100 nM, but was inhibited at 1 and 10 μM
(Table 1). Dipyridamole is also known to be a useful inhibitor
for distinguishing human ENT1 from ENT2, since it blocks
human ENT1 and ENT2 with a Ki of 5 nM and 360 nM,
respectively [24]. However, in the rat, there are some
contradictory reports about the ability of dipyridamole to
inhibit rat ENT-mediated transport. The inhibitory effect
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[26] and rat brain microvascular endothelial cells [27,28] as well
as the TR-iBRB2 cells in this study, while 1 μM dipyridamole
had no effect on transport activity in recombinant rat ENT1 and
ENT2 expressed in Xenopus oocytes [23]. These observations
indicate that dipyridamole is an effective inhibitor of ENT2-
mediated transport in the case of TR-iBRB2 cells, although its
inhibitory effect seems to depend on the cell type and
preparation used.
[3H]Adenosine is transported from the circulating blood to
the retina across the BRB with an apparent influx clearance of
11.1±4.1 μL/(min g retina) (Fig. 5). This value is far greater
than that of [14C]sucrose [0.26 μL/(min g retina)] and [3H]D-
mannitol [0.75 μL/(min g retina)] used as non-permeable
paracellular markers [29]. The RUI value of [3H]adenosine was
also greater than that of [3H]D-mannitol (Table 2). These results
suggest that adenosine is transported via a carrier-mediated
transport process, rather than by passive diffusion. Moreover,
[3H]adenosine uptake into the retina was inhibited by adenosine
and thymidine, but was unaffected by cytidine (Table 2). These
inhibitory characteristics are comparable with those obtained in
TR-iBRB2 cells (Table 1). The BRB is composed of retinal
capillary endothelial cells (inner BRB) and retinal pigment
epithelial cells (outer BRB). In addition to TR-iBRB2 cells (Fig.
2), carrier-mediated adenosine transport has also been demon-
strated in ARPE-19 cells, an in vitro model of the human outer
BRB [30]. Accordingly, both the inner and outer BRB seem to
be involved in [3H]adenosine transport from the circulating
blood to the retina. The net flux of adenosine transport at the
BRB is still uncertain at the present time, since it is technically
impossible to estimate the efflux clearance across the BRB. In
the case of the blood–brain barrier (BBB), the efflux clearance
of adenosine across the BBB is 3-fold greater than the influx
clearance [31]. The adenosine concentration in the rat retina/
choroid [32] (approximately 0.9 nmol/g ≈ 0.9 μM) is about 10-
fold greater than that in the blood (90 nM) [31]. Since the Km of
adenosine uptake by TR-iBRB2 cells (28.5 μM; Fig. 3) is
greater than the adenosine concentration in the retina/choroid as
well as the blood, the transport velocity of adenosine at the inner
BRB is expected to be relative to the adenosine concentration.
Therefore, the net efflux of adenosine transport at the inner BRB
may occur as at the BBB [31], since ENT2 is a bi-directional
equilibrative transporter.
In conclusion, adenosine transport at the inner BRB is most
likely mediated by ENT2. Under physiological conditions,
adenosine serves as the principal mechanism of inhibitory
neuromodulation [33]. However, the adenosine concentration is
dramatically increased by more than 10-fold in the ischemic
retina [32] and then adenosine exacerbates the effects of retinal
ischemia/reperfusion and promotes retinal neovascularization
[2,34]. Therefore, the possible physiological role for ENT2 at
the inner BRB involves maintaining a constant milieu of
adenosine in the retinal interstitial fluid especially under some
pathological conditions like ischemia. The current findings
represent an important contribution to our understanding of the
physiological roles of the inner BRB in regulating the adenosine
concentration in the retina.Acknowledgements
The authors would like to thank Dr. Kazunori Katayama
(University of Toyama) and Yoshiharu Deguchi (Teikyo
University) for valuable discussions. This study was supported,
in part, by a Grant-in-Aid for Scientific Research from the Japan
Society for the Promotion of Science and a grant for Research
on Sensory and Communicative Disorders by the Ministry of
Health, Labor, and Welfare, Japan.
References
[1] G.A. Lutty, D.S. McLeod, Retinal vascular development and oxygen-
induced retinopathy: a role for adenosine, Prog. Retin. Eye Res. 22 (2003)
95–111.
[2] G.J. Ghiardi, J.M. Gidday, S. Roth, The purine nucleoside adenosine in
retinal ischemia–reperfusion injury, Vis. Res. 39 (1999) 2519–2535.
[3] G.W. Kreutzberg, S.T. Hussain, Cytochemical heterogeneity of the glial
plasma membrane: 5′-nucleotidase in retinal Müller cells, J. Neurocytol.
11 (1982) 53–64.
[4] G.A. Lutty, C. Merges, D.S. McLeod, 5′ nucleotidase and adenosine
during retinal vasculogenesis and oxygen-induced retinopathy, Investig.
Ophthalmol. Vis. Sci. 41 (2000) 218–229.
[5] L. Sosula, P. Beaumont, K.M. Jonson, F.C. Hollows, Quantitative
ultrastructure of capillaries in the rat retina, Invest. Ophthalmol. 11 (1972)
916–925.
[6] K. Hosoya, M. Tomi, Advances in the cell biology of transport via the
inner blood–retinal barrier: establishment of cell lines and transport
functions, Biol. Pharm. Bull. 28 (2005) 1–8.
[7] E. Polska, P. Ehrlich, A. Luksch, G. Fuchsjager-Mayrl, L. Schmetterer,
Effects of adenosine on intraocular pressure, optic nerve head blood flow,
and choroidal blood flow in healthy humans, Investig. Ophthalmol. Vis.
Sci. 44 (2003) 3110–3114.
[8] S.A. Baldwin, P.R. Beal, S.Y. Yao, A.E. King, C.E. Cass, J.D. Young, The
equilibrative nucleoside transporter family, SLC29, Pflugers Arch. 447
(2004) 735–743.
[9] J.H. Gray, R.P. Owen, K.M. Giacomini, The concentrative nucleoside
transporter family, SLC28, Pflugers Arch. 447 (2004) 728–734.
[10] M.A. Ackley, R.J. Governo, C.E. Cass, J.D. Young, S.A. Baldwin, A.E.
King, Control of glutamatergic neurotransmission in the rat spinal dorsal
horn by the nucleoside transporter ENT1, J. Physiol. 548 (2003) 507–517.
[11] B.J. Meester, N.P. Shankley, N.J. Welsh, F.L. Meijler, J.W. Black,
Pharmacological analysis of the activity of the adenosine uptake inhibitor,
dipyridamole, on the sinoatrial and atrioventricular nodes of the guinea-
pig, Br. J. Pharmacol. 124 (1998) 729–741.
[12] C. Blazynski, The accumulation of [3H]phenylisopropyl adenosine ([3H]
PIA) and [3H]adenosine into rabbit retinal neurons is inhibited by
nitrobenzylthioinosine (NBI), Neurosci. Lett. 121 (1991) 1–4.
[13] R. Paes de Carvalho, K.M. Braas, S.H. Snyder, R. Adler, Analysis of
adenosine immunoreactivity, uptake, and release in purified cultures of
developing chick embryo retinal neurons and photoreceptors, J. Neuro-
chem. 55 (1990) 1603–1611.
[14] K. Hosoya, M. Tomi, S. Ohtsuki, H. Takanaga, M. Ueda, N. Yanai, M.
Obinata, T. Terasaki, Conditionally immortalized retinal capillary
endothelial cell lines (TR-iBRB) expressing differentiated endothelial
cell functions derived from a transgenic rat, Exp. Eye Res. 72 (2001)
163–172.
[15] K. Hosoya, A. Minamizono, K. Katayama, T. Terasaki, M. Tomi, Vitamin
C transport in oxidized form across the rat blood–retinal barrier, Investig.
Ophthalmol. Vis. Sci. 45 (2004) 1232–1239.
[16] T. Nakashima, M. Tomi, K. Katayama, M. Tachikawa, M. Watanabe, T.
Terasaki, K. Hosoya, Blood-to-retina transport of creatine via creatine
transporter (CRT) at the rat inner blood–retinal barrier, J. Neurochem. 89
(2004) 1454–1461.
[17] M. Tomi, M. Mori, M. Tachikawa, K. Katayama, T. Terasaki, K. Hosoya,
L-Type amino acid transporter 1 (LAT1)-mediated L-leucine transport at
19K. Nagase et al. / Biochimica et Biophysica Acta 1758 (2006) 13–19the inner blood–retinal barrier, Investig. Ophthalmol. Vis. Sci. 46 (2005)
2522–2530.
[18] T. Kitano, H. Iizasa, T. Terasaki, T. Asashima, N. Matsunaga, N. Utoguchi,
Y. Watanabe, M. Obinata, M. Ueda, E. Nakashima, Polarized glucose
transporters and mRNA expression properties in newly developed rat
syncytiotrophoblast cell lines, TR-TBTs, J. Cell. Physiol. 193 (2002)
208–218.
[19] K. Yamaoka, Y. Tanigawara, T. Nakagawa, T. Uno, A pharmacokinetic
analysis program (multi) for microcomputer, J. Pharmacobio-dyn. 4 (1981)
879–885.
[20] Y.S. Kang, T. Terasaki, A. Tsuji, Acidic drug transport in vivo through the
blood–brain barrier. A role of the transport carrier for monocarboxylic
acids, J. Pharmacobio-dyn. 13 (1990) 158–163.
[21] A. Alm, P. Törnquist, The uptake index method applied to studies on the
blood–retinal barrier. I. A methodological study, Acta Physiol. Scand. 113
(1981) 73–79.
[22] E. Snoeck, K. Ver Donck, P. Jacqmin, H. Van Belle, A.G. Dupont, A. Van
Peer, M. Danhof, Physiological red blood cell kinetic model to explain the
apparent discrepancy between adenosine breakdown inhibition and
nucleoside transporter occupancy of draflazine, J. Pharmacol. Exp. Ther.
286 (1998) 142–149.
[23] S.Y. Yao, A.M. Ng, W.R. Muzyka, M. Griffiths, C.E. Cass, S.A. Baldwin,
J.D. Young, Molecular cloning and functional characterization of
nitrobenzylthioinosine (NBMPR)-sensitive (es) and NBMPR-insensitive
(ei) equilibrative nucleoside transporter proteins (rENT1 and rENT2) from
rat tissues, J. Biol. Chem. 272 (1997) 28423–28430.
[24] J.L. Ward, A. Sherali, Z.P. Mo, C.M. Tse, Kinetic and pharmacological
properties of cloned human equilibrative nucleoside transporters, ENT1
and ENT2, stably expressed in nucleoside transporter-deficient PK15 cells.
ENT2 exhibits a low affinity for guanosine and cytidine but a high affinity
for inosine, J. Biol. Chem. 275 (2000) 8375–8381.
[25] S.Y. Yao, A.M. Ng, M.F. Vickers, M. Sundaram, C.E. Cass, S.A. Baldwin,
J.D. Young, Functional and molecular characterization of nucleobasetransport by recombinant human and rat equilibrative nucleoside
transporters 1 and 2. Chimeric constructs reveal a role for the ENT2
helix 5–6 region in nucleobase translocation, J. Biol. Chem. 277 (2002)
24938–24948.
[26] C.J. Sinclair, C.G. LaRiviere, J.D. Young, C.E. Cass, S.A. Baldwin, F.
E. Parkinson, Purine uptake and release in rat C6 glioma cells:
nucleoside transport and purine metabolism under ATP-depleting
conditions, J. Neurochem. 75 (2000) 1528–1538.
[27] M. Chishty, D.J. Begley, N.J. Abbott, A. Reichel, Functional characterisa-
tion of nucleoside transport in rat brain endothelial cells, NeuroReport 14
(2003) 1087–1090.
[28] F.E. Parkinson, J. Friesen, L. Krizanac-Bengez, D. Janigro, Use of a three-
dimensional in vitro model of the rat blood–brain barrier to assay
nucleoside efflux from brain, Brain Res. 980 (2003) 233–241.
[29] S.L. Lightman, A.G. Palestine, S.I. Rapoport, E. Rechthand, Quantitative
assessment of the permeability of the rat blood–retinal barrier to small
water-soluble non-electrolytes, J. Physiol. 389 (1987) 483–490.
[30] S. Majumdar, S. Macha, D. Pal, A.K. Mitra, Mechanism of ganciclovir
uptake by rabbit retina and human retinal pigmented epithelium cell line
ARPE-19, Curr. Eye Res. 29 (2004) 127–136.
[31] A.J. Isakovic, N.J. Abbott, Z.B. Redzic, Brain to blood efflux transport of
adenosine: blood–brain barrier studies in the rat, J. Neurochem. 90 (2004)
272–286.
[32] S. Roth, P.S. Rosenbaum, J. Osinski, S.S. Park, A.Y. Toledano, B. Li, A.A.
Moshfeghi, Ischemia induces significant changes in purine nucleoside
concentration in the retina-choroid in rats, Exp. Eye Res. 65 (1997)
771–779.
[33] E.A. Newman, Glial cell inhibition of neurons by release of ATP,
J. Neurosci. 23 (2003) 1659–1666.
[34] R.P. Mino, P.E. Spoerri, S. Caballero, D. Player, L. Belardinelli, I.
Biaggioni, M.B. Grant, Adenosine receptor antagonists and retinal
neovascularization in vivo, Investig. Ophthalmol. Vis. Sci. 42 (2001)
3320–3324.
